A New Blood Test Predicts Alzheimer’s With 90% Accuracy

A New Blood Test Predicts Alzheimer’s With 90% Accuracy

AGENCE FRANCE PRESSE SCIENCE  MAR. 10, 2014, 6:32 PM

Researchers in the United States say they have developed a prototype blood test that can tell with 90-percent accuracy whether a healthy person will develop Alzheimer’s disease within three years.

The test looks for 10 signatures of fatty proteins called lipids, according to a study published on Sunday in the journal Nature Medicine.

It could help families of people developing the cognitive disorder make early decisions on how best to care for them and may also aid the search for treatment, the authors said.

Several years of clinical trials are likely to be needed to assess the prototype technique, the first blood “bio-marker” to predict the tragic degenerative disease.

Alzheimer’s, caused by toxic proteins that destroy brain cells, is a currently incurable and fatal degenerative disease.

Around 35 million people have the disease, a tally that is expected to reach 115 million people by 2050, according to the World Health Organization.

“Our novel blood test offers the potential to identify people at risk for progressive cognitive decline and can change how patients, their families and treating physicians plan for and manage the disorder,” said Howard Federoff, a professor of neurology at Georgetown University Medical Center in Washington.

It could also help efforts to treat the disease, he said in a press release.

Attempts to develop drugs for Alzheimer’s have failed possibly because they are tested when the disease has progressed too far, Federoff said.

These treatments may have a better chance of braking or reversing the disease if they are trialled at a much earlier stage, he said.

The researchers started by taking blood samples from 525 healthy volunteers aged 70 and older.

Three years later, they looked at a group of 53 volunteers who had developed symptoms of early Alzheimer’s or a memory-affecting condition known as amnestic mild cognitive impairment (aMCI).

The blood samples from this group were compared against the samples from 53 otherwise healthy volunteers to see what the difference was.

From this, the scientists spotted the 10 telltale lipid proteins, which appear to be metabolized residues of brain cell membranes.

 

Unknown's avatarAbout bambooinnovator
Kee Koon Boon (“KB”) is the co-founder and director of HERO Investment Management which provides specialized fund management and investment advisory services to the ARCHEA Asia HERO Innovators Fund (www.heroinnovator.com), the only Asian SMID-cap tech-focused fund in the industry. KB is an internationally featured investor rooted in the principles of value investing for over a decade as a fund manager and analyst in the Asian capital markets who started his career at a boutique hedge fund in Singapore where he was with the firm since 2002 and was also part of the core investment committee in significantly outperforming the index in the 10-year-plus-old flagship Asian fund. He was also the portfolio manager for Asia-Pacific equities at Korea’s largest mutual fund company. Prior to setting up the H.E.R.O. Innovators Fund, KB was the Chief Investment Officer & CEO of a Singapore Registered Fund Management Company (RFMC) where he is responsible for listed Asian equity investments. KB had taught accounting at the Singapore Management University (SMU) as a faculty member and also pioneered the 15-week course on Accounting Fraud in Asia as an official module at SMU. KB remains grateful and honored to be invited by Singapore’s financial regulator Monetary Authority of Singapore (MAS) to present to their top management team about implementing a world’s first fact-based forward-looking fraud detection framework to bring about benefits for the capital markets in Singapore and for the public and investment community. KB also served the community in sharing his insights in writing articles about value investing and corporate governance in the media that include Business Times, Straits Times, Jakarta Post, Manual of Ideas, Investopedia, TedXWallStreet. He had also presented in top investment, banking and finance conferences in America, Italy, Sydney, Cape Town, HK, China. He has trained CEOs, entrepreneurs, CFOs, management executives in business strategy & business model innovation in Singapore, HK and China.

Leave a comment